Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13648687 | 1.00 | KDM4E (0.44) | KDM4EGLATP53EGFRITK | |
| SCHEMBL13648686 | 0.93 | SMN1; SMN2 (0.47) | KDM4EEGFRITKSMN1; SMN2PRMT5 | |
| SCHEMBL13648685 | 0.93 | SMN1; SMN2 (0.47) | KDM4EEGFRITKSMN1; SMN2PRMT5 | |
| SCHEMBL14355396 | 0.91 | KDM4E (0.44) | KDM4EGLATP53SMN1; SMN2PRMT5 | |
| SCHEMBL14355400 | 0.91 | KDM4E (0.44) | KDM4EGLATP53SMN1; SMN2PRMT5 | |
| SCHEMBL13648386 | 0.90 | L3MBTL1 (0.52) | SMN1; SMN2SYK | |
| SCHEMBL14498895 | 0.90 | TSHR (0.44) | KDM4ESMN1; SMN2PRMT5WDR77ALDH1A1 | |
| SCHEMBL14498894 | 0.89 | KMT2A (0.42) | TP53EGFRITKSMN1; SMN2LMNA | |
| SCHEMBL13648375 | 0.88 | MEN1 (0.43) | EGFRBTK | |
| SCHEMBL13648363 | 0.88 | KDM4E (0.55) | KDM4ETP53SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | KDM4E 767/4885GLA 2351/4885TP53 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.